EB病毒阳性与阴性原发性中枢神经系统淋巴瘤的表观遗传和转录谱差异
研究对23例EBV阴性和15例EBV阳性原发性中枢神经系统淋巴瘤(弥漫大B细胞淋巴瘤)进行RNA测序和EPIC甲基化芯片分析,发现两者在转录和表观遗传上可清晰区分,EBV阳性者整体启动子甲基化降低,CD79B启动子高甲基化与其转录下调高度相关。
要点
- EBV阳性和阴性PCNSL分属不同的转录和甲基化聚类(P<.0001)。
- EBV阴性者BCR和WNT/β-catenin信号增强,EBV阳性者IL-10、NOTCH和病毒生命周期通路上调。
- EBV阳性PCNSL整体启动子甲基化降低,CD79B启动子高甲基化与其转录下调相关(R=-0.7)。
核心结论
- EBV阳性和阴性PCNSL具有不同的转录和表观遗传谱,证实二者为不同的生物学亚型。
研究设计与样本
- 研究纳入23例EBV阴性和15例EBV阳性PCNSL(组织学均为弥漫大B细胞淋巴瘤),进行RNA测序和EPIC甲基化芯片分析,并行无监督聚类分析。
主要发现
- 发现两个转录聚类可将EBV阴性和EBV阳性PCNSL分开(P<.0001)。
- EBV阳性转录特征包含受EBV癌基因调控的基因(GPR15、FCER2/CD23、SLAMF1/CD150)。
- EBV阴性淋巴瘤中B细胞受体(BCR)和WNT/β-catenin信号通路增强,EBV阳性者中IL-10、NOTCH和病毒生命周期通路上调。
- EBV阴性肿瘤中BCR相关的SYK激酶活性富集,EBV阳性PCNSL中JAK2过表达。
- EBV阳性PCNSL整体启动子甲基化降低;两个甲基化聚类可将EBV阴性和EBV阳性PCNSL分开(P<.0001);CD79B启动子高甲基化与其在EBV阳性PCNSL中的转录下调高度相关(R=-0.7)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Epstein-Barr virus (EBV)+ and EBV- primary CNS lymphomas (PCNSL) carry distinct mutational landscapes, but their transcriptional and epigenetic profiles have not been integrated and compared. This precludes further insights into pathobiology and molecular differences, relevant for classification and targeted therapy. METHODS: Twenty-three EBV- and 15 EBV+ PCNSL, histologically classified as diffuse large B-cell lymphomas, were subjected to RNA-sequencing and EPIC methylation arrays. Unsupervised clustering analyses were performed. Differentially expressed and differentially methylated genes were identified and integrated. RESULTS: Two distinct transcriptional clusters were found, which separated EBV- and EBV+ PCNSL (P < .0001). The EBV+ transcriptional signature contained genes (GPR15, FCER2/CD23, SLAMF1/CD150) closely regulated by EBV oncogenes in B cells. Pathway enrichment analysis uncovered enhanced B-cell receptor (BCR) and WNT/beta-catenin signaling in EBV- lymphomas, whereas Interleukin-10, NOTCH, and viral life cycle pathways were upregulated in EBV+ PCNSL. Correspondingly, BCR-associated SYK kinase activity was enriched in EBV- tumors while JAK2 was overrepresented in EBV+ PCNSL. Epigenetic profiling revealed reduced global promoter methylation in EBV+ PCNSL. Two methylation clusters were recognized, which separated EBV- and EBV+ PCNSL (P < .0001). Epigenetic profiles were distinct from 2,788 other brain tumor and nonmalignant reference samples. Promoter region hypermethylation of CD79B, a BCR subunit critical for sustained proliferation in EBV- disease, highly correlated (R = -0.7) with its transcriptional downregulation in EBV+ PCNSL. CONCLUSIONS: EBV+ and EBV- PCNSL harbor distinct transcriptional and epigenetic profiles, corroborating them as distinctive biological subtypes. Uncovered differences provide novel insights into their pathobiology, may guide molecular diagnostics and targeted therapies.
引用
- Hai L, Friedel D, Hinz F, et al. Distinct epigenetic and transcriptional profiles of Epstein-Barr virus-positive and negative primary CNS lymphomas. Neuro Oncol. 2025. PMID: 39575767. doi:10.1093/neuonc/noae251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。